Thimmaiah Chendrimada
Founder Able Sciences
Seminars
Thursday 3rd December 2026
Evaluating RNA-Based In Vivo CAR-T Platforms Against Established Delivery Technologies
12:00 pm
- Comparing RNA and lentiviral delivery approaches to understand trade-offs in durability, safety, and clinical applicability, enabling informed platform selection
- Exploring delivery challenges for in vivo immune cell engineering, including assessing approaches to improve targeting and manufacturability for broader therapeutic use
- Leveraging early clinical insights on safety and efficacy endpoints to guide platform positioning and inform transition from oncology into autoimmune applications
